Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent

The development of a murine model of Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA + type I, and CagA − type II in vi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2001-09, Vol.19 (32), p.4883-4895
Hauptverfasser: Kleanthous, Harry, Tibbitts, Timothy J, Gray, Heather L, Myers, Gwendolyn A, Lee, Cynthia K, Ermak, Thomas H, Monath, Thomas P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4895
container_issue 32
container_start_page 4883
container_title Vaccine
container_volume 19
creator Kleanthous, Harry
Tibbitts, Timothy J
Gray, Heather L
Myers, Gwendolyn A
Lee, Cynthia K
Ermak, Thomas H
Monath, Thomas P
description The development of a murine model of Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA + type I, and CagA − type II in vivo adapted isolates. In vivo passage of a type II H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10 7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10 4–10 5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different Helicobacter strains that can influence the outcome of both infection and immunity.
doi_str_mv 10.1016/S0264-410X(01)00248-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71145617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X01002481</els_id><sourcerecordid>18107265</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EotvCTwD5AiqHgMefyalCFVCkShwKEjfLcSaLkeMEO4tYfj1ud0WPPfkwzztjPS8hL4C9BQb63Q3jWjYS2PdzBm8Y47Jt4BHZQGtEwxW0j8nmP3JCTkv5yRhTArqn5ARACSUk3xC8WTGHGP6GtKVhmnYprHvqti6kslL8s9TphGl1kV5hDH7una8JuuzjnAMNaUS_hjnRUKj_4WLEtMWmrLkuoAMumIaafkaejC4WfH58z8i3jx--Xl41118-fb58f914yfnamF55qWTbM9YPPSijO6kF51x4ZVoxum7EOkJwqsVRCe3AmVG7Yei0Yb0TZ-T1Ye-S5187LKudQvEYo0s474o1AFJpMA-C0AIzXKsKqgPo81xKxtEuVYjLewvM3hZh74qwt5YtA3tXhIWae3k8sOsnHO5TR_MVeHUEXPEujtklH8o9JyvYMVa5iwOH1dvvgNkWHzB5HEKu6u0whwe-8g-IHKba</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18107265</pqid></control><display><type>article</type><title>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kleanthous, Harry ; Tibbitts, Timothy J ; Gray, Heather L ; Myers, Gwendolyn A ; Lee, Cynthia K ; Ermak, Thomas H ; Monath, Thomas P</creator><creatorcontrib>Kleanthous, Harry ; Tibbitts, Timothy J ; Gray, Heather L ; Myers, Gwendolyn A ; Lee, Cynthia K ; Ermak, Thomas H ; Monath, Thomas P</creatorcontrib><description>The development of a murine model of Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA + type I, and CagA − type II in vivo adapted isolates. In vivo passage of a type II H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10 7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10 4–10 5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different Helicobacter strains that can influence the outcome of both infection and immunity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(01)00248-1</identifier><identifier>PMID: 11535342</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Administration, Oral ; Administration, Rectal ; Animals ; Animals, Outbred Strains ; Antigens, Bacterial - genetics ; Antigens, Bacterial - immunology ; Bacterial diseases ; Bacterial Proteins - analysis ; Bacterial Proteins - genetics ; Bacterial Proteins - immunology ; Bacterial Proteins - physiology ; Bacteriology ; Biological and medical sciences ; Cat Diseases - microbiology ; Cats ; Experimental bacterial diseases and models ; Fundamental and applied biological sciences. Psychology ; Gastric Mucosa - immunology ; Gastric Mucosa - microbiology ; Gastritis - microbiology ; Gastritis - therapy ; Gastritis - veterinary ; Helicobacter ; Helicobacter Infections - microbiology ; Helicobacter Infections - therapy ; Helicobacter Infections - veterinary ; Helicobacter pylori ; Helicobacter pylori - classification ; Helicobacter pylori - enzymology ; Helicobacter pylori - genetics ; Helicobacter pylori - immunology ; Helicobacter pylori - isolation &amp; purification ; Helicobacter pylori - pathogenicity ; Immunity ; Immunization - methods ; Immunotherapy, Active ; Infectious diseases ; Macaca mulatta ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Microbiology ; Monkey Diseases - microbiology ; Mouth Mucosa - immunology ; Phenotype ; Pyloric Antrum - microbiology ; Recombinant Fusion Proteins - genetics ; Recombinant Fusion Proteins - immunology ; Urease - analysis ; Urease - genetics ; Urease - physiology ; Vaccine ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Virulence - immunology</subject><ispartof>Vaccine, 2001-09, Vol.19 (32), p.4883-4895</ispartof><rights>2001 Elsevier Science Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</citedby><cites>FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X01002481$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14153900$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11535342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kleanthous, Harry</creatorcontrib><creatorcontrib>Tibbitts, Timothy J</creatorcontrib><creatorcontrib>Gray, Heather L</creatorcontrib><creatorcontrib>Myers, Gwendolyn A</creatorcontrib><creatorcontrib>Lee, Cynthia K</creatorcontrib><creatorcontrib>Ermak, Thomas H</creatorcontrib><creatorcontrib>Monath, Thomas P</creatorcontrib><title>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>The development of a murine model of Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA + type I, and CagA − type II in vivo adapted isolates. In vivo passage of a type II H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10 7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10 4–10 5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different Helicobacter strains that can influence the outcome of both infection and immunity.</description><subject>Administration, Oral</subject><subject>Administration, Rectal</subject><subject>Animals</subject><subject>Animals, Outbred Strains</subject><subject>Antigens, Bacterial - genetics</subject><subject>Antigens, Bacterial - immunology</subject><subject>Bacterial diseases</subject><subject>Bacterial Proteins - analysis</subject><subject>Bacterial Proteins - genetics</subject><subject>Bacterial Proteins - immunology</subject><subject>Bacterial Proteins - physiology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Cat Diseases - microbiology</subject><subject>Cats</subject><subject>Experimental bacterial diseases and models</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gastric Mucosa - immunology</subject><subject>Gastric Mucosa - microbiology</subject><subject>Gastritis - microbiology</subject><subject>Gastritis - therapy</subject><subject>Gastritis - veterinary</subject><subject>Helicobacter</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter Infections - therapy</subject><subject>Helicobacter Infections - veterinary</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - classification</subject><subject>Helicobacter pylori - enzymology</subject><subject>Helicobacter pylori - genetics</subject><subject>Helicobacter pylori - immunology</subject><subject>Helicobacter pylori - isolation &amp; purification</subject><subject>Helicobacter pylori - pathogenicity</subject><subject>Immunity</subject><subject>Immunization - methods</subject><subject>Immunotherapy, Active</subject><subject>Infectious diseases</subject><subject>Macaca mulatta</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microbiology</subject><subject>Monkey Diseases - microbiology</subject><subject>Mouth Mucosa - immunology</subject><subject>Phenotype</subject><subject>Pyloric Antrum - microbiology</subject><subject>Recombinant Fusion Proteins - genetics</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Urease - analysis</subject><subject>Urease - genetics</subject><subject>Urease - physiology</subject><subject>Vaccine</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Virulence - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EotvCTwD5AiqHgMefyalCFVCkShwKEjfLcSaLkeMEO4tYfj1ud0WPPfkwzztjPS8hL4C9BQb63Q3jWjYS2PdzBm8Y47Jt4BHZQGtEwxW0j8nmP3JCTkv5yRhTArqn5ARACSUk3xC8WTGHGP6GtKVhmnYprHvqti6kslL8s9TphGl1kV5hDH7una8JuuzjnAMNaUS_hjnRUKj_4WLEtMWmrLkuoAMumIaafkaejC4WfH58z8i3jx--Xl41118-fb58f914yfnamF55qWTbM9YPPSijO6kF51x4ZVoxum7EOkJwqsVRCe3AmVG7Yei0Yb0TZ-T1Ye-S5187LKudQvEYo0s474o1AFJpMA-C0AIzXKsKqgPo81xKxtEuVYjLewvM3hZh74qwt5YtA3tXhIWae3k8sOsnHO5TR_MVeHUEXPEujtklH8o9JyvYMVa5iwOH1dvvgNkWHzB5HEKu6u0whwe-8g-IHKba</recordid><startdate>20010914</startdate><enddate>20010914</enddate><creator>Kleanthous, Harry</creator><creator>Tibbitts, Timothy J</creator><creator>Gray, Heather L</creator><creator>Myers, Gwendolyn A</creator><creator>Lee, Cynthia K</creator><creator>Ermak, Thomas H</creator><creator>Monath, Thomas P</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20010914</creationdate><title>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</title><author>Kleanthous, Harry ; Tibbitts, Timothy J ; Gray, Heather L ; Myers, Gwendolyn A ; Lee, Cynthia K ; Ermak, Thomas H ; Monath, Thomas P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Administration, Oral</topic><topic>Administration, Rectal</topic><topic>Animals</topic><topic>Animals, Outbred Strains</topic><topic>Antigens, Bacterial - genetics</topic><topic>Antigens, Bacterial - immunology</topic><topic>Bacterial diseases</topic><topic>Bacterial Proteins - analysis</topic><topic>Bacterial Proteins - genetics</topic><topic>Bacterial Proteins - immunology</topic><topic>Bacterial Proteins - physiology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Cat Diseases - microbiology</topic><topic>Cats</topic><topic>Experimental bacterial diseases and models</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gastric Mucosa - immunology</topic><topic>Gastric Mucosa - microbiology</topic><topic>Gastritis - microbiology</topic><topic>Gastritis - therapy</topic><topic>Gastritis - veterinary</topic><topic>Helicobacter</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter Infections - therapy</topic><topic>Helicobacter Infections - veterinary</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - classification</topic><topic>Helicobacter pylori - enzymology</topic><topic>Helicobacter pylori - genetics</topic><topic>Helicobacter pylori - immunology</topic><topic>Helicobacter pylori - isolation &amp; purification</topic><topic>Helicobacter pylori - pathogenicity</topic><topic>Immunity</topic><topic>Immunization - methods</topic><topic>Immunotherapy, Active</topic><topic>Infectious diseases</topic><topic>Macaca mulatta</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microbiology</topic><topic>Monkey Diseases - microbiology</topic><topic>Mouth Mucosa - immunology</topic><topic>Phenotype</topic><topic>Pyloric Antrum - microbiology</topic><topic>Recombinant Fusion Proteins - genetics</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Urease - analysis</topic><topic>Urease - genetics</topic><topic>Urease - physiology</topic><topic>Vaccine</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Virulence - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kleanthous, Harry</creatorcontrib><creatorcontrib>Tibbitts, Timothy J</creatorcontrib><creatorcontrib>Gray, Heather L</creatorcontrib><creatorcontrib>Myers, Gwendolyn A</creatorcontrib><creatorcontrib>Lee, Cynthia K</creatorcontrib><creatorcontrib>Ermak, Thomas H</creatorcontrib><creatorcontrib>Monath, Thomas P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kleanthous, Harry</au><au>Tibbitts, Timothy J</au><au>Gray, Heather L</au><au>Myers, Gwendolyn A</au><au>Lee, Cynthia K</au><au>Ermak, Thomas H</au><au>Monath, Thomas P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2001-09-14</date><risdate>2001</risdate><volume>19</volume><issue>32</issue><spage>4883</spage><epage>4895</epage><pages>4883-4895</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>The development of a murine model of Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA + type I, and CagA − type II in vivo adapted isolates. In vivo passage of a type II H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10 7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10 4–10 5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different Helicobacter strains that can influence the outcome of both infection and immunity.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>11535342</pmid><doi>10.1016/S0264-410X(01)00248-1</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2001-09, Vol.19 (32), p.4883-4895
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_71145617
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Administration, Oral
Administration, Rectal
Animals
Animals, Outbred Strains
Antigens, Bacterial - genetics
Antigens, Bacterial - immunology
Bacterial diseases
Bacterial Proteins - analysis
Bacterial Proteins - genetics
Bacterial Proteins - immunology
Bacterial Proteins - physiology
Bacteriology
Biological and medical sciences
Cat Diseases - microbiology
Cats
Experimental bacterial diseases and models
Fundamental and applied biological sciences. Psychology
Gastric Mucosa - immunology
Gastric Mucosa - microbiology
Gastritis - microbiology
Gastritis - therapy
Gastritis - veterinary
Helicobacter
Helicobacter Infections - microbiology
Helicobacter Infections - therapy
Helicobacter Infections - veterinary
Helicobacter pylori
Helicobacter pylori - classification
Helicobacter pylori - enzymology
Helicobacter pylori - genetics
Helicobacter pylori - immunology
Helicobacter pylori - isolation & purification
Helicobacter pylori - pathogenicity
Immunity
Immunization - methods
Immunotherapy, Active
Infectious diseases
Macaca mulatta
Medical sciences
Mice
Mice, Inbred C57BL
Microbiology
Monkey Diseases - microbiology
Mouth Mucosa - immunology
Phenotype
Pyloric Antrum - microbiology
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - immunology
Urease - analysis
Urease - genetics
Urease - physiology
Vaccine
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Virulence - immunology
title Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T06%3A58%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sterilizing%20immunity%20against%20experimental%20Helicobacter%20pylori%20infection%20is%20challenge-strain%20dependent&rft.jtitle=Vaccine&rft.au=Kleanthous,%20Harry&rft.date=2001-09-14&rft.volume=19&rft.issue=32&rft.spage=4883&rft.epage=4895&rft.pages=4883-4895&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(01)00248-1&rft_dat=%3Cproquest_cross%3E18107265%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18107265&rft_id=info:pmid/11535342&rft_els_id=S0264410X01002481&rfr_iscdi=true